Addressing Real-world Challenges in Neovascular Eye Diseases with New Treatment Regimens - CME - Guideline Central

CME

Title
Addressing Real-world Challenges in Neovascular Eye Diseases with New Treatment Regimens
Link
Description
Intravitreally administered anti-vascular endothelial growth factor (anti-VEGF) therapies have transformed the treatment landscape for neovascular age-related macular degeneration (nAMD), and diabetic macular edema (DME). However, clinicians need ongoing education on these emerging therapies and the real-world patient experiences with them. An expert panel of two ophthalmologists will explore how anti-angiogenesis agents can help reduce treatment burden faced by patients while achieving optimal vision outcomes. This educational session will help clinicians understand the magnitude of the burden of retinal diseases and to emphasize the urgency of early diagnosis and evidence-based treatments to reduce frequent visits and improve patient outcomes.
Target Audience
The educational design of this activity addresses the needs of ophthalmology clinicians, retinal specialists (MD/DO/nurse practitioners/physician assistants) and optometry clinicians, and optometrists.
Learning Objectives
  • Discuss factors, including pathophysiologic factors, that prevent people with nAMD or DME from obtaining vision and anatomic benefits comparable to those seen in clinical trials with standard anti-VEGF regimen
  • Summarize the roles of ang-2 and VEGF pathways in vascular instability, inflammation, and fibrosis in neovascular eye diseases
  • Synthesize data from clinical trials and real-world evidence with new anti-angiogenesis agents in treatment-naïve and experienced eyes with nAMD or DME
Estimated Duration
45 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Ophthalmology
Keywords
Neovascular Eye Diseases
Disclosures and Disclaimers
Disclosures: All relevant financial relationships for anyone with the ability to control the content of this educational activity have been mitigated. Disclaimer: Content is current as of the date this activity was released. The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.
Accredited Providers
  • Global Education Group
  • MedliveCME
  • New England College of Optometry (NECO)
Commercial Support
  • Genentech
Activity Expiration Date
October 2, 2026
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit0.75 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.